ǰÑÔ
°×Ѫ²¡(leukemia)ÊÇÔìѪ×éÖ¯µÄ¶ñÐÔÔöÖ³ÐÔ¼²²¡£¬ÆäÌØµãÊǹÇËè¼°ÆäËûÔìѪ×éÖ¯Öдó×ÚÎÞºËϸ°ûÎÞÏÞÖÆÔöÉú£¬½øÈëÍâÖÜѪҺ£¬ÁÙ´²ÌåÏÖÒÔ¹ÇË衢Ƣ¡¢¸ÎµÈÔìѪÆ÷¹ÙÖеİ×Ѫ²¡Ï¸°û¶ñÐÔÔöÉúÓëÖ״󣬲¢½þÈóµ½È«Éí¸÷×éÖ¯ÔàÆ÷ÖУ¬°éÓвî±ðˮƽµÄѪÐé¡¢³öѪ¡¢Ñ¬È¾·¢ÈÈÒÔ¼°¹Ç÷ÀÌÛÍ´¡£°×Ѫ²¡µÄ·¢²¡ÂʺÍéæÃüÂÊÖðÄêÔöÌí£¬¾Ó35ËêÒÔÏÂÇàÉÙÄê¶ñÐÔÖ×ÁöµÄÊ×λ¡£Òò´Ë£¬ÖƱ¸ÏìÓ¦µÄ¶¯ÎïÄ£×Ó¶ÔÆäÑо¿¾ßÓÐÖ÷ÒªµÄÒâÒå¡£¾ø´ó´ó¶¼ÈËÀà°×Ѫ²¡¿ÉÒÔÓû¯Ñ§£¨ÈçÉÕ»¯¼Á£©¡¢ÎïÀí£¨ÈçµçÀë·øÉ䣩¡¢ÉúÎÈ練ת¼²¡¶¾£©ÒÔ¼°×ª»ùÒòÒªÁ죬ÔÚ²î±ð¶¯ÎСÊó¡¢ëàÊó¡¢´óÊó¡¢Ã¨¡¢Å£¡¢³¤±ÛÔ³µÈ£©ÖÐÓÕ·¢°×Ѫ²¡£¬½¨É趯ÎïÄ£×Ó¡£
AKR×Ô¾õÐÔ°×Ѫ²¡Ð¡Êó³öÉúʱ¼´´øÓÐÖ°©µÄRNA²¡¶¾£¬¶ÔÒ©ÎïµÄÖÎÁÆ·´Ó¦ÀàËÆ¶ùͯ¼±ÐÔÁܰÍϸ°û°×Ѫ²¡(acute lymphoblastic leukemia,ALL)¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
AKRСÊóΪ°×Ѫ²¡¸ß·¢Æ·Ïµ£¬ÁܰÍϸ°û°×Ѫ²¡·¢²¡ÂÊÐÛÐÔΪ76%~90%£¬´ÆÐÔΪ68%~90%¡£6~12ÔÂÁäAKRСÊó·ºÆðÆ¢ºÍÁÜͶºÏÖ×´ó£¬ÑªÏóÒì³£¡£¸÷¸öСÊó°×Ѫ²¡µÄ²¡³Ì·×Æç£¬¾ÑªÒº¼ì²éÈ·ÕïΪ°×Ѫ²¡ºóµÄÔ½ÈÕ£¬¼´¿ÉÅä¶Ô·Ö×é²¢×îÏȸøÓèÊÜÊÔÒ©£¬ÊÓ²ìЧ¹û¡£ÊÓ²ìÖ¸±ê°üÀ¨Ä©ÉÒѪÏó¡¢°×ϸ°ûÊý¡¢ÁÜͶºÏºÍÆ¢¾Þϸ¡¢¶¯ÎïÉúÑÄʱ¼ä¡£ÓÐÓÃÕßÉúÑÄÆÚ±È±ÈÕÕ×éÑÓÉ죬²¢Æ¾Ö¤ÑªÏóÆÀ¼ÛÒ©ÎïµÄÓÕµ¼»º½âºÍά³Ö»º½âµÄ×÷Óá£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
AKRСÊó°×Ѫ²¡Ä£×ÓµÄ×Ô¾õÐÔÖ×Áöͨ³£±ÈÓÃʵÑéÒªÁìÓÕ·¢µÄÖ×ÁöÓëÈËÀàËù»¼µÄÖ×Áö¸üΪÏàËÆ£¬ÓÐÀûÓÚ½«¶¯ÎïʵÑéЧ¹ûÍÆÓõ½ÈË£»ÇÒÆäÖ×Áö±¬·¢µÄÌõ¼þ½ÏÁ¿×ÔÈ»£¬ÓпÉÄÜͨÏ꾡ÖÂÊÓ²ìºÍͳ¼ÆÆÊÎö¶ø·¢Ã÷ÔÀ´Ã»Óз¢Ã÷µÄÇéÐεĻòÆäËûµÄÖ°©ÒòËØ£¬¿ÉÒÔ×ÅÖØÊÓ²ìÒÅ´«ÒòËØÔÚÖ×Áö±¬·¢ÉϵÄ×÷Ó᣶¯Îï×Ô¾õÐÔÖ×ÁöµÄ²¡ÒòÍùÍùÊÇÓɶ¯ÎïµÄÒÅ´«ÌØÕ÷¾öÒéµÄ£¬ÓëÈËÀàËù»¼Ö×ÁöµÄ²¡ÒòÓнϴó¾àÀë¡£²î±ð¶¯ÎïÖ×ÁöÉú³¤ËÙÂʲî±ð½Ï´ó£¬ºÜÄÑÔÚÏÞÖÆÊ±¼äÄÚ»ñµÃ´ó×îÉú³¤ÔȳƵĺÉÁö¶¯ÎÔì³ÉÊÓ²ìʱ¼ä¿ÉÄܽϳ¤¡¢ÊµÑéãýÃð½Ï´óµÈȱÏÝ¡£Òò´Ë£¬×Ô¾õÐÔÖ×Áö¶¯ÎïÄ£×ÓºÜÉÙÔÚ¿¹Ö×ÁöÒ©ÎïµÄͨÀýɸѡÖÐÆÕ±éÓ¦Óá£
²Î¿¼ÎÄÏ×£º
1.µËÑï¼Î£¬ÐìÒèÖ¥£¬Â¦ÊÀ·æ£®¼±ÐÔËèÐÔ°×Ѫ²¡SCIDСÊóÄ£×ӵĽ¨Éè¼°Åжϣ®ÏÖ´úÉúÎïҽѧϣÍû£¬2008,8(1): 53-55
2.ÖìÓñ·å£¬ÍõÔªÕ¼£¬ÃÏ·²Ò壮BCR/ABLת»ùÒò¶¯ÎïÄ£×ÓÑо¿Ï£Íû¼°Ó¦Óã®ÖйúʵÑéѪҺѧÔÓÖ¾£¬2011,19 (6):1532-1535
3.Áõ࣬¼¾Ã÷´º£¬Àîºñ´ï. ÈËÂýÐÔÁ£Ï¸°û°×Ѫ²¡¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2005,15 (1):55-58
4.ÀîÀöϼ£¬ÌÀÓÀÃñ£¬¹ËΰÖÒ£¬µÈ£®¼±ÐÔBÁܰÍϸ°û°×Ѫ²¡¶¯ÎïÄ£×ӵĽ¨Éè. Õã½´óѧѧ±¨£ºÒ½Ñ§°æ£¬2008,37(5): 511-514
5.ÑîÏþöï. Ö£¾þËÉ£¬ÕÅУ¬µÈ£®GITR¿¹Ìå¶ÔL615°×Ѫ²¡ÒÖÖÆ×÷ÓõÄʵÑéÑо¿. µÚÈý¾üÒ½´óѧѧ±¨£¬2006,28 (18):1837-1841
6.ÖÜÏþÑ࣬×ÞÁÕ£®°×Ѫ²¡Ð¡ÊóÄ£×ӵĽ¨ÉèÓëÓ¦ÓÃÏÖ×´£®·Ö×ÓÕï¶ÏÓëÖÎÁÆÔÓÖ¾£¬2011,3 (3):212-216
7.Ohsugi T, Yamaguchi K, Kumasaka T, et a]_ Rapid tumor death model for evalualion of new therapeutic agents for adult T-cell leukemia. Lab Invest,2004, 84 (2): 263-266
8.Ramshaw HS, Bardy PG, Lee MA, el al. Chronic myelomoaocylic leukemia requires granulocyte macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol,2002,30(10):1124-1131
9.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem, 2009, 284 (2):913-920
10.Xu D,Wang S,Yu WM,et al. A germline gain-offunction mutation in Ptpn 11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hemalopoielic stem cells. Blood, 2010, 116(18):3611-3621